Positive initial data demonstrated pharmacologically relevant exposures Management and key opinion leaders to present complete…
Presentations include recently updated results from the skin cancer cohort of IGNYTE, an ongoing Phase…
Target tumor reductions observed in advanced malignant PEComa patients harboring TSC1 or TSC2 inactivating alterations…
Preliminary results represent the first clinical evidence of targeting a p53 Y220C mutation ASCO abstract…
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) — Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage…
Design and rationale of the phase 1/2a open label, multicenter study of the AFM24 monotherapy…
Phase 1b/2 Study of Etigilimab and Nivolumab in Subjects with Select Locally Advanced or Metastatic…
Preliminary data from first 19 patients treated with PDS0101 in combination with KEYTRUDA® (pembrolizumab) demonstrates…
77% of checkpoint inhibitor (CPI) refractory patients alive at median follow up of 12 months…
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Checkmate Pharmaceuticals, Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biotechnology company…
Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with…
BOSTON, May 26, 2022 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical…
CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq:RUBY), a clinical-stage biopharmaceutical…
Overall response rate of 14% and disease control rate of 36% in Part B of…
Preclinical data from a study of the Company’s pan-RAF product candidate, KIN-2787, in combination with…
Clinically active and well tolerated in patients with solid tumors Favorable safety profile emerging: 22%…
NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) — IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical…
– First clinical data demonstrating potential of SAFEbody technology platform to create…
Data demonstrate that SOT101 monotherapy and SOT101 in combination with pembrolizumab have a favorable safety…
– SRF388 demonstrated clinical activity in multiple solid tumor types withthree confirmed partial responses across…